Risks of AMR
AMR poses the threat of a "post-antibiotic era" where antimicrobials will no longer be effective against infections caused by resistant pathogens. Resistant bacteria are harder to treat and increase morbidity, mortality and healthcare costs.
In the USA, AMR is already associated with 2.8 million infections and 35,000 deaths every year (2). And in Europe, AMR is linked to €1.5 billion in extra healthcare costs and productivity loss (3).
Research & surveillance
Learn on demand
Clinical diagnostics
In particular, multiplex PCR panel tests, also known as syndromic tests, provide quick and definitive pathogen identification that enables rational antimicrobial use.
Multiplex PCR panel testing can support antimicrobial stewardship efforts by (8–11)*:
- Improving appropriate antiviral treatment and reducing unnecessary antibiotic use (8, 11)
- Reducing antibiotic treatment duration and ancillary testing (9–11)
- Providing rapid results to support clinical decision-making (8, 11)
Learn on demand
References
* Unless otherwise stated, data cited pertains to the use of a device from another manufacturer.
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor).